133 Molesworth Street
PO Box 5013
Wellington 6140
New Zealand
T +64 4 496 2000
W www.medsafe.govt.nz
24 February 2022
Maxwell
By email: [FYI request #17981 email]
Ref:
H202117877
Dear Maxwell
Response to your request for official information
Thank you for your request under the Official Information Act 1982 (the Act) on 17 December
2021 for:
“The full meeting minutes from the 113th meeting of the Medicines Assessment Advisory
Committee held on 14 December 2021 as outlined in the agenda
(https://www.medsafe.govt.nz/committees/maac/Agenda113-14Dec21.htm).
Please include all relevant correspondence (supporting evidence, email/text
communications, memorandum, etc) for any applications for consent to distribute a new
medicine under Section 20 / 23 / 24 of the Medicines Act 1981 that were discussed during
the meeting in question.”
Information within scope of your request is itemised in Appendix 1 of this letter and copies of the
documents are enclosed. The table in Appendix 1 outlines the grounds under which I have
decided to withhold information. Where information is withheld, this is noted in the document
itself.
I trust this information fulfils your request. Under section 28(3) of the Act, you have the right to
ask the Ombudsman to review any decisions made under this request. The Ombudsman may be
contacted by email at:
[email address] or by calling 0800 802 602.
Please note that this response, with your personal details removed, may be published on the
Ministry website at:
www.health.govt.nz/about-ministry/information-releases.
Yours sincerely
Chris James
Group Manager
Medsafe
Appendix 1: List of documents for release
#
Date
Document details
Decision on release
1
14 December Minutes of the 113th meeting of
Some information withheld under
2021
the Medicines Assessment
section 9(2)(g)(ii) of the Act to
Advisory Committee
maintain the effective conduct of
public affairs through the protection
of such Ministers, members of
organisations, officers, and
employees from improper pressure
or harassment.
2
N/A
Medsafe Evaluation Report -
Some information withheld under the
Clinical
following sections of the Act:
• 9(2)(a) to protect the privacy of
natural persons
• 9(2)(b)(ii) where its release would
likely unreasonably prejudice the
commercial position of the
person who supplied the
information.
3
N/A
Medsafe Evaluation Report -
Some information withheld under
Quality
section 9(2)(b)(ii) of the Act.
4
N/A
Information supplied by Pfizer
Withheld in full under section
New Zealand in support of its
9(2)(b)(ii) of the Act..
application
Page 2 of 2